Evidence map›Paper›PMID 28031178›Full record

ArticleClinical and vaccine immunology : CVI2017

Otitis-Prone Children Produce Functional Antibodies to Pneumolysin and Pneumococcal Polysaccharides.

Lea-Ann S Kirkham, Selma P Wiertsema, Karli J Corscadden, Tulia Mateus, Gemma L Mullaney, Guicheng Zhang, Peter C Richmond, Ruth B Thornton

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Panel 8: Vaccines and immunology.International journal of pediatric otorhinolaryngology · 2020
    Review
  4. Panel 7 - Pathogenesis of otitis media - a review of the literature between 2015 and 2019.International journal of pediatric otorhinolaryngology · 2020
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Lea-Ann S KirkhamSchool of Paediatrics and Child Health, University of Western Australia, Perth, Australia lea-ann.kirkham@uwa.edu.au.
Selma P WiertsemaSchool of Paediatrics and Child Health, University of Western Australia, Perth, Australia.
Karli J CorscaddenWesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia.
Tulia MateusSchool of Paediatrics and Child Health, University of Western Australia, Perth, Australia.
Gemma L MullaneySchool of Paediatrics and Child Health, University of Western Australia, Perth, Australia.
Guicheng ZhangSchool of Paediatrics and Child Health, University of Western Australia, Perth, Australia.
Peter C RichmondSchool of Paediatrics and Child Health, University of Western Australia, Perth, Australia.
Ruth B ThorntonSchool of Paediatrics and Child Health, University of Western Australia, Perth, Australia.
University of Western Australia · AUThe Kids Research Institute Australia · AUCurtin University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pneumococcus is a major otitis media (OM) pathogen, but data are conflicting regarding whether otitis-prone children have impaired humoral immunity to pneumococcal antigens. We and others have shown that otitis-prone and healthy children have similar antibody titers to pneumococcal proteins and polysaccharides (vaccine and nonvaccine types); however, the quality of antibodies from otitis-prone children has not been investigated. Antibody function, rather than titer, is considered to be a better correlate of protection from pneumococcal disease. Therefore, we compared the capacities of antibodies from otitis-prone (cases) and healthy (controls) children to neutralize pneumolysin, the pneumococcal toxin currently in development as a vaccine antigen, and to opsonize pneumococcal vaccine and nonvaccine serotypes. A pneumolysin neutralization assay was conducted on cholesterol-depleted complement-inactivated sera from 165 cases and 61 controls. A multiplex opsonophagocytosis assay (MOPA) was conducted on sera from 20 cases and 20 controls. Neutralizing and opsonizing titers were calculated with antigen-specific IgG titers to determine antibody potency for pneumolysin, pneumococcal conjugate vaccine (PCV) polysaccharides, and non-PCV polysaccharides. There was no significant difference in antibody potencies between cases and controls for the antigens tested. Antipneumolysin neutralizing titers increased with the number of episodes of acute OM, but antibody potency did not. Pneumolysin antibody potency was lower in children colonized with pneumococci than in noncarriers, and this was significant for the otitis-prone group (

Indexed as

Antibodies, BacterialBacterial ProteinsChild, PreschoolCross-Sectional StudiesFemaleHumansImmunoglobulin GInfantMaleNeutralization TestsOpsonin ProteinsOtitisPhagocytosisPneumococcal InfectionsPolysaccharides, BacterialStreptolysinsAntibodies, BacterialBacterial ProteinsImmunoglobulin GOpsonin ProteinsplY protein, Streptococcus pneumoniaePolysaccharides, BacterialStreptolysinsantibody functionantibody potencyneutralizing titeropsonophagocytosisotitis mediapneumococcal conjugate vaccinepneumococcal polysaccharidespneumolysinrAOMStreptococcus pneumoniaevaccines

Identifiers

PMID28031178
PMCPMC5339643
OpenAlexW2565322628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.